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Human MxA (MX1) protein is an interferon-induced restriction factor for a diverse range of viruses, whereas
the related MxB (MX2) protein was thought to lack such activity. Three recent papers, including one in this
issue of Cell Host & Microbe, show that MxB inhibits human immunodeficiency virus type 1 (HIV-1) infection.Myxovirus resistance (Mx) proteins are
IFN-induced dynamin-like large GTPases
of vertebrates (Haller and Kochs (2011).
Most mammals have two Mx genes
(myxovirus resistance genes 1 and 2)
that arose by gene duplication. The hu-
man MxA protein (encoded by the MX1
gene) has long been recognized as a
potent cell-autonomous restriction factor
with antiviral activity against a range
of pathogenic DNA and RNA viruses,
notably influenza A viruses (Ma¨nz et al.,
2013). In contrast, MxB (encoded by the
MX2 gene and closely linked to MX1 on
chromosome 21) was found to be devoid
of antiviral activity and was considered
to serve cellular functions, such as regu-
lating nucleo-cytoplasmic transport and
cell-cycle progression (King et al., 2004;
Mele´n et al., 1996). Liu et al. (2013) now
report in this issue of Cell Host & Microbe
that MxB (MX2) is an innate immunity
factor that blocks HIV-1 infection. Two
other recent reports published in Nature
(Goujon et al., 2013; Kane et al., 2013)
come to the same conclusion. These
unexpected findings represent a major
advance in our understanding of anti-
retroviral host defense and may provide
clues for designing new strategies to
combat HIV-1 and AIDS.
The human MX genes were cloned at
the University of Zu¨rich, Switzerland,almost 25 years ago (Aebi et al., 1989),
at a time when the AIDS epidemic was
gaining momentum worldwide. How is it
possible that the anti-HIV-1 activity of
MxB remained undetected for such a
long time? MxB was perhaps neglected
owing to the preconceived notion that it
was not antiviral or it was outright missed
because it displays its antiviral function
preferentially in some cell types but not
others. In retrospect, it makes sense that
MxB is part of the IFN-induced antiviral
state, as it was sporadically identified in
large scale screens for IFN-induced anti-
viral factors.
MxA and MxB are closely related (63%
amino acid sequence identity) and share
a similar domain structure and archi-
tecture (Figures 1A and 1B). The crystal
structure of MxA revealed three functional
domains, namely the amino-terminal
globular ‘‘G domain’’ that binds and
hydrolyses GTP, a hinge-like ‘‘bundle
signaling element’’ (BSE) that connects
the ‘‘G domain’’ to the elongated ‘‘stalk’’
domain, and the helical ‘‘stalk,’’ which
mediates self-assembly into oligomers
and serves antiviral effector functions
(Gao et al., 2011). The predicted structure
of MxB is almost superimposable with
that of MxA (Figure 1B). A unique feature
of MxB is that it exists in two isoforms
that are translated as 78 or 76 kDa pro-teins from alternate AUG start codons of
the same mRNA (Mele´n et al., 1996). The
longer isoform contains a nuclear locali-
zation signal (NLS)-like sequence in its
first 25 amino acids and appears to
localize preferentially to nuclear pores,
whereas the 76 kDa form is cytoplasmic.
Recent structural and evolutionary
studies identified critical antiviral speci-
ficity determinants in MxA. A disordered
loop, called L4 that is also present in
MxB protrudes from the stalk (Figure 1B).
An analysis of MxA orthologs from simian
primates identified L4 as a target interface
under positive selection and revealed that
variations in L4 dictate antiviral specificity
toward orthomyxoviruses (Mitchell et al.,
2012). Additional ‘‘hot spots’’ of positive
selection may represent alternative target
specificity determinants.
Now, Liu et al. (2013) demonstrate that
MxB, but not MxA, inhibits the replication
of a well-known HIV-1 strain (NL4-3) in
cell culture. Expression of MxB inhibited
HIV-1 growth in a permissive CD4+ T cell
line while depletion of endogenous MxB
reduced the anti-HIV-1 effect of IFN-a in
a human astroglioma cell line known to
respond well to IFN treatment. These and
additional experiments clearly demon-
strate that MxB is responsible for a large
part of the antiretroviral effect induced by
type I IFNs. It was conceivable that MxB, October 16, 2013 ª2013 Elsevier Inc. 371
Figure 1. Predicted Structure and Anti-HIV-1 Action of Human MxB GTPase
(A) Domain structure of the two different MxB isoforms translated from alternate start codons, with the amino-terminal nuclear localization signal (+NLS, light
green box) or without (NLS), in comparison to MxA. B indicates the sequences that form the BSE.
(B) Structural models of human MxB(+NLS), MxB(NLS), and the related MxA GTPase, predicted by http://zhanglab.ccmb.med.umich.edu/I-TASSER and
PyMOL software.
(C) Schematic diagram showing IFN-induced MxB and other factors (red circles) known to restrict different steps in the HIV-1 life cycle. A3G, APOBEC3G.
Viral escape strategies counteracting restriction factors (e.g., viral antagonists or resistance mutations in the viral capsid) are depicted by green exit squares.
MxB affects the nuclear uptake and/or stability of the HIV-1 replication complex and the subsequent chromosomal integration of the proviral DNA.
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into the cell, analogous to the proposed
mode of MxA action against othomyxovir-
ues. To assess this possibility, the authors
took various approaches and came to the
conclusion that the peptidyl-prolyl-isom-
erase cyclophilin A (CypA), a known inter-
actor of the viral capsid protein (CA), is
involved in the anti-HIV-1 activity of MxB.
They isolated an escape virus after pro-
longed passages of HIV-1 through MxB-
expressing cells that carried a single mu-
tation altering CA at residue A88, which
is indispensable for CypA binding. Thus,
CypA binding to the HIV-1 capsid appears
to be required for MxB restriction. Further
experiments indicated that CypA is un-
likely to directly bridge MxB to the viral
target but that it may modify the confor-
mation of the capsid in such a way that it
becomes accessible for MxB, as has
been proposed for the restriction factor
TRIM5a. Intruigingly, MxB was found to
be incorporated into newly formed HIV-1
particles even in the presence of cyclo-
sporin A, an inhibitor of CypA, indicating
that MxB associates in a CypA-indepen-
dent manner with viral component(s) dur-
ing packaging.372 Cell Host & Microbe 14, October 16, 201Which step in the HIV-1 replication cy-
cle is inhibited by MxB? Liu et al. (2013)
demonstrate that MxB does not affect
the synthesis or accumulation of reverse
transcription products nor the generation
of viral 2-long terminal repeat (2-LTR) cir-
cular DNA, a process that occurs in the
cell nucleus. Instead, MxB blocked spe-
cifically the accumulation of integrated,
proviral DNA. The authors conclude that
MxB does not inhibit nuclear entry of
HIV-1 DNA but impairs its chromosomal
integration.
This conclusion is challenged by the
reports of Goujon et al. (2013) and Kane
et al. (2013), both published recently in
Nature. Goujon et al. (2013) identified
MX2 among a number of genes highly up-
regulated by IFNa in HIV-1-restricting cell
lines by means of transcriptional profiling
and established beyond doubt that MxB
(referred to as MX2) is a key effector of
the innate immune system against HIV-
1. They had previously set the stage for
the RNA-profiling approach by defining
the variations in IFN responsiveness of
different cell types (Goujon and Malim
(2010)). In a series of elegant and well-
controlled experiments, they now demon-3 ª2013 Elsevier Inc.strate that MxB suppresses all HIV-1
strains tested and, to a lesser extent,
HIV-2 as well as simian immunodefi-
ciency viruses but not other retroviruses.
Mutations in the capsid protein (P90A,
N74D), which is known to prevent the
interaction with CypA and other cellular
factors including some nucleoporins and
cleavage and polyadenylation specificity
factor-6, caused escape fomMxB restric-
tion. Thus, all three studies suggest that
MxB targets the viral capsid. In contrast
to Liu et al. (2013), however, Goujon
et al. (2013) report that MxB strongly
reduced the levels of 2-LTR circles and
thus conclude that MxB blocks nuclear
uptake of viral replication complexes or
affects their stability. In this respect
MxB restriction differs from TRIM5a-,
APOBEC3G-, SAMHD1- or Tetherin-
mediated restriction (Figure 1C). The
same conclusion was reached by Kane
et al. (2013). They characterized a variety
of viral escape mutants and also
concluded that mutations in the capsid
protein that affect binding to cellular fac-
tors involved in nuclear import pathways
confer some MxB resistance. Interest-
ingly, they report that the anti-HIV-1
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cells and depends on the N-terminal
sequence containing the NLS. Surpris-
ingly, however, both groups demonstrate
that MxB mutants unable to bind or hy-
drolyse GTP retain their anti-HIV-1 activ-
ity. This is a remarkable property for a dy-
namin-like GTPase because nucleotide-
regulated self-assembly and disassembly
is thought to be critical for proper function
of this class of effector molecules. Com-
parablemutations inMxA result in inactive
proteins (Ponten et al., 1997). It may well
be that the MxB mutants exert the
observed effect by their propensity to
disturb intracellular protein trafficking
and nuclear import (King et al., 2004).
Many open questions remain and are
expected to stimulate research activities
on MxB and the Mx GTPases in general.
MxB may become another example of
the ‘‘arms race’’ between host and virus,
with retroviruses as the driving force in
co-evolution. A great hope is that these
findings will turn out to have clinicaland epidemiological relevance and can
be exploited to control HIV infections
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